| Mr Corey Louis Hartman, MD | |
|
3415 Independence Drive, Suite 200, Birmingham, AL 35209 | |
| (205) 871-7332 | |
| (205) 871-7336 |
| Full Name | Mr Corey Louis Hartman |
|---|---|
| Gender | Male |
| Speciality | Dermatology |
| Experience | 22 Years |
| Location | 3415 Independence Drive, Suite 200, Birmingham, Alabama |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1124078902 | NPI | - | NPPES |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Dclh, Inc. | 8527104488 | 6 |
News Archive
Scientists at the University at Buffalo have identified the mechanisms behind a genetic mutation that produces certain autistic behaviors in mice, as well as therapeutic strategies to restore normal behaviors.
The biological diversity of organisms on earth is not just something we enjoy when taking a walk through a blossoming meadow in spring; it is also the basis for countless products and services provided by nature, including food, building materials, and medicines as well as the self-purifying qualities of water and protection against erosion.
Eli Lilly and Company announced today that the United States Food and Drug Administration (FDA) has approved Strattera (atomoxetine HCI) for maintenance treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in children and adolescents. Strattera, a selective norepinephrine reuptake inhibitor, is the first FDA-approved non-stimulant to treat ADHD in children, adolescents and adults.
Clorox Professional Products Company, a division of The Clorox Company, will showcase Clorox Healthcare, its new strengthened comprehensive product offerings and educational initiatives to meet healthcare professionals' diverse needs, at the Association for Professionals in Infection Control and Epidemiology (APIC) 2012 Conference in San Antonio, Texas, June 4-6.
Patients with advanced cancers who took a drug designed to relieve constipation caused by pain killers lived longer and had fewer reports of tumor progression than cancer patients who did not receive the drug, according to results presented October 27 at the 2015 meeting of the American Society of Anesthesiologists in San Diego. This is the first study in humans to associate opioid blockade with improved survival.
› Verified 3 days ago
| Entity Name | Dclh, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1265663926 PECOS PAC ID: 8527104488 Enrollment ID: O20091006000592 |
News Archive
Scientists at the University at Buffalo have identified the mechanisms behind a genetic mutation that produces certain autistic behaviors in mice, as well as therapeutic strategies to restore normal behaviors.
The biological diversity of organisms on earth is not just something we enjoy when taking a walk through a blossoming meadow in spring; it is also the basis for countless products and services provided by nature, including food, building materials, and medicines as well as the self-purifying qualities of water and protection against erosion.
Eli Lilly and Company announced today that the United States Food and Drug Administration (FDA) has approved Strattera (atomoxetine HCI) for maintenance treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in children and adolescents. Strattera, a selective norepinephrine reuptake inhibitor, is the first FDA-approved non-stimulant to treat ADHD in children, adolescents and adults.
Clorox Professional Products Company, a division of The Clorox Company, will showcase Clorox Healthcare, its new strengthened comprehensive product offerings and educational initiatives to meet healthcare professionals' diverse needs, at the Association for Professionals in Infection Control and Epidemiology (APIC) 2012 Conference in San Antonio, Texas, June 4-6.
Patients with advanced cancers who took a drug designed to relieve constipation caused by pain killers lived longer and had fewer reports of tumor progression than cancer patients who did not receive the drug, according to results presented October 27 at the 2015 meeting of the American Society of Anesthesiologists in San Diego. This is the first study in humans to associate opioid blockade with improved survival.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mr Corey Louis Hartman, MD Dclh, Inc Dba/skin Wellness Dermatology, 3415 Independence Drive, Suite 200, Birmingham, AL 35209 Ph: (205) 871-7332 | Mr Corey Louis Hartman, MD 3415 Independence Drive, Suite 200, Birmingham, AL 35209 Ph: (205) 871-7332 |
News Archive
Scientists at the University at Buffalo have identified the mechanisms behind a genetic mutation that produces certain autistic behaviors in mice, as well as therapeutic strategies to restore normal behaviors.
The biological diversity of organisms on earth is not just something we enjoy when taking a walk through a blossoming meadow in spring; it is also the basis for countless products and services provided by nature, including food, building materials, and medicines as well as the self-purifying qualities of water and protection against erosion.
Eli Lilly and Company announced today that the United States Food and Drug Administration (FDA) has approved Strattera (atomoxetine HCI) for maintenance treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in children and adolescents. Strattera, a selective norepinephrine reuptake inhibitor, is the first FDA-approved non-stimulant to treat ADHD in children, adolescents and adults.
Clorox Professional Products Company, a division of The Clorox Company, will showcase Clorox Healthcare, its new strengthened comprehensive product offerings and educational initiatives to meet healthcare professionals' diverse needs, at the Association for Professionals in Infection Control and Epidemiology (APIC) 2012 Conference in San Antonio, Texas, June 4-6.
Patients with advanced cancers who took a drug designed to relieve constipation caused by pain killers lived longer and had fewer reports of tumor progression than cancer patients who did not receive the drug, according to results presented October 27 at the 2015 meeting of the American Society of Anesthesiologists in San Diego. This is the first study in humans to associate opioid blockade with improved survival.
› Verified 3 days ago
Callie Roberts Hill, Dermatology Medicare: Medicare Enrolled Practice Location: 1927 1st Ave N, Birmingham, AL 35203 Phone: 205-933-0987 Fax: 205-930-1750 | |
Carly Elston, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 500 22nd St S, Birmingham, AL 35233 Phone: 205-934-9999 | |
Tiffany Mayo, Dermatology Medicare: Accepting Medicare Assignments Practice Location: 1717 6th Ave S, Birmingham, AL 35233 Phone: 800-822-8816 | |
Daniel Bergman, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 619 19th St S, Birmingham, AL 35249 Phone: 205-934-4011 Fax: 205-297-9411 | |
Carlton Phillips, Dermatology Medicare: Accepting Medicare Assignments Practice Location: 2100 16th Ave S, Birmingham, AL 35205 Phone: 205-933-0987 Fax: 205-930-1758 | |
Katherine Flanagan, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 813 Shades Creek Pkwy, Suite 205, Birmingham, AL 35209 Phone: 205-578-1799 Fax: 205-578-3158 | |
Vijay Balakrishnan, MD Dermatology Medicare: Medicare Enrolled Practice Location: 510 20th St S Ste 858, Birmingham, AL 35233 Phone: 205-934-5188 |